AlphAIalphai — Financial news for AI agents
finanznachrichten.deJUN 124 min read$IVA

INVENTIVA: Inventiva announces Repayment of EIB Loans, Repurchase of a portion of EIB Warrants and the Issuance of the first two tranches under New Debt Financing

Inventiva said it completed key steps of a combined EIB and new debt financing transaction on June 12, 2026. It prepaid EIB loans of about €62.2m and repurchased/cancelled EIB warrants for €50m (including 700,000 Tranche B warrants). It issued Tranche A convertible bonds (€35m) and Tranche B amortized bonds (€40m) for €71.3m net proceeds, with conversion price €5.2893 and lender warrant exercise price €4.1559.

Original reporting
finanznachrichten.de
Published Jun 12, 2026, 9:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 12, 2026, 9:23 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
INVENTIVA: Inventiva announces Repayment of EIB Loans, Repurchase of a portion of EIB Warrants and the Issuance of the first two tranches under New Debt Financing — source image
Source · finanznachrichten.de
Decision brief

The 30-second read

$IVANeutralMed
01

Why it matters

The company reports completion of the EIB settlement and issuance of the first two debt tranches, with explicit conversion ratio and lender warrant exercise price, effectively locking in the capital-structure changes.

02

Market read

Traders can update financing/dilution expectations using the disclosed €75m debt issuance, €62.2m EIB loan payoff, and the specific €5.2893 conversion price and €4.1559 warrant exercise price.

03

What to watch

Remaining EIB warrants require shareholder approval for cancellation; timing of the June 30, 2026 general meeting could create additional event risk/volatility.

Relevance 8/10Novelty 8/10Timing: post-close June 12, 2026 financing steps (after equity offering settled June 5)

Background

Inventiva previously announced a combined transaction (EIB loan repayment/warrant repurchase plus new debt tranches) contingent on completing an equity financing of at least €90m.

Company-level read

Ticker impact

$IVANeutralMedium confidence
Context

Inventiva completed repayment of €62.2m EIB loans, repurchased EIB warrants for €50m, and issued €75m Tranche A/B debt with set conversion/exercise prices.

Expected impact

Likely near-term volatility around dilution/financing overhang, with potential support if traders view the financing as extending runway and removing EIB overhang.

Evidence & confidence

The article discloses concrete financing mechanics (amounts, conversion price €5.2893, warrant exercise price €4.1559) and that EIB loans/warrants were settled, which can re-rate risk and dilution expectations.

Market effects

Sector

Biopharma financing via EIB + convertible/amortized tranches signals continued reliance on structured capital to fund late-stage trials; may affect read-across for other clinical-stage issuers’ financing terms.

Regional

Supports sentiment for Euronext/Nasdaq-listed small/mid-cap biotechs completing structured financings.

Global

Limited beyond structured-debt/convertible market participants tracking conversion/warrant pricing and secured lender terms.

Counterpoint

What could challenge this read

The conversion price and warrant exercise price are set at premiums to the equity offering price, which could reduce immediate dilution pressure versus lower-priced deals.

Key entities

  • company
    Inventiva

    Clinical-stage biopharma focused on oral therapy for MASH; completed EIB repayment/warrant repurchase and issued Tranche A/B debt.

  • lender
    European Investment Bank (EIB)

    Provided loans and warrants that were prepaid/repurchased as part of the transaction.

  • lenders
    BlackRock and Claret Capital Partners

    Managed funds/accounts that subscribed to the debt tranches and received lender warrants.

Read at source← All news

Related articles

JUL 30
$IVAMed

INVENTIVA: Correction: Inventiva Announces Preliminary Financial Results for the First Half of 2026

Cash and cash equivalents at €166.1 million and €67.8 million in short-term deposits2 as at June 30, 2026 Daix (France), New York City (New York, United States), July 30, 2026 - Update to Press Release Dated July 29, 2026. The Company wishes to correct an error in the press release issued on July 29, 2026. On page 2, the potential proceeds for the Tranche C of the Debt Financing Transaction was mistakenly stated as €20 million. The correct figure is €55 million.

finanznachrichten.de4 min
JUL 29
$IVAMed

INVENTIVA: Inventiva Announces Preliminary Financial Results for the First Half of 2026

Inventiva (Euronext Paris and Nasdaq: IVA) reported preliminary 1H 2026 results. Cash and cash equivalents were €166.1 million at June 30, 2026, versus €99.3 million at Dec. 31, 2025. Net cash used in operating activities was (€48.7) million. R&D expenses were (€50.1) million. No revenues were recorded. The company expects funding into Q2 2027, or Q1 2028 with potential tranches.

finanznachrichten.de4 min
JUN 23
$IVAMedAI 8/10

Gide advises Inventiva on a comprehensive capital structure optimization including debt and equity financing Gide

Gide advised Inventiva, a biopharmaceutical company, on combined cross-border financing. According to Gide, Inventiva raised about $120m via an offering of American depositary shares in the U.S., and arranged new bond and convertible bond financing of €75m initially (up to €130m subject to conditions). The transactions also included a €50m repurchase of EIB warrants and full repayment of existing EIB debt. Cooley advised on U.S. law.

gide.com2 min
JUN 12
$IVAMedAI 8/10

Inventiva announces Repayment of EIB Loans, Repurchase of a portion of EIB Warrants and the Issuance of the first two tranches under New Debt Financing

Inventiva said it completed June 12, 2026 steps of its EIB and new debt financing. According to the company, it repaid EIB loans in full for about €62.2m and repurchased/cancelled EIB warrants for €50m (including 700,000 Tranche B warrants). It also issued Tranche A €35m convertible bonds and Tranche B €40m amortized bonds for initial gross proceeds €75m, with net proceeds €71.3m.

manilatimes.net4 min